Establishment of clinical criteria: Best practice, clinical guidelines and patient pathways European Reference Networks, Brussels, June 23 rd 2014 Dr Judith Richardson, Associate Director Pathways, Health and Social Care
Overview The role of NICE Clinical guidelines Involving the public Guidance into practice Do clinical guidelines make a difference? The future some challenges
NICE The National Institute for Health and Care Excellence (NICE) is the independent organisation in the UK responsible for providing national guidance and advice on promoting high quality health, public health and social care.
The beginning NICE was launched in 1999 as the National Institute for Clinical Excellence to drive the uptake of new technologies across the NHS and standardise care. Initial work programme was the development of recommendations on new technologies, based on an assessment of clinical and cost effectiveness. Guidance NHS & pa/ents
Followed by. significant growth 250 200 150 More guidance for the NHS: clinical guidelines, interventional procedures, medical technologies Public health guidance Implementation programme NHS Evidence and the National Electronic Library for Medicines and accreditation The British National Formulary transfer National Prescribing Centre Quality standards 100 50 0 2000/1 2001/2 2002/3 2003/4 2004/5 2005/6 2006/7 2007/8 2008/9 2009/10 2010/11
Core principles of all NICE guidance Comprehensive evidence base Expert input Patient and carer involvement Independent advisory committees Genuine consultation Regular review Open and transparent process Social values and equity considerations
NICE guidance: clinical guidelines NICE clinical guidelines recommend the best ways to diagnose, treat and care for people with par/cular diseases and condi/ons, in the NHS.
Why develop guidelines? Inappropriate variations in clinical practice Persisting use of ineffective treatments Need to apply established treatments of proven clinical and cost effectiveness Failure to adopt clinically and cost effective new treatments Post-code prescribing (particularly in the UK) Impossible for clinicians to read and appraise all relevant evidence themselves.
Developing a NICE guideline - key principles The guideline needs to be useful to the NHS should improve decisions and hence patients outcomes should promote the cost-effective use of NHS resources but... It is not a textbook needs to cover the remit but needs to focus on key areas of known variation or uncertainty have in the past avoided issues of service delivery Based on best available evidence & GDG consensus the process needs to be systematic & transparent
Components of the guideline - recommendations Based on balance of evidence on benefits, harms & costs Where evidence is missing, poor or conflicting consider recommendations based on GDG consensus Also consider research recommendations Consider not to do as well as to do recommendations
How do NICE committees produce guidance? Evidence reviewed Draft recommendations Update decision Consultation Guidance published
Guideline development 4 months Dra: scope Final scope Stakeholder comments Scoping 13-16 months GDG develops guideline Consulta2on on dra: guideline Consulta2on on dra: guideline Stakeholder comments Development 9 months Revise guideline a:er comments Pre- publica2on check Prepare and publish guideline Valida2on Final guideline published Publica2on and dissemina2on
Costs - Producing Guidance How much does it cost? Disease/problem Affected population Burden of disease (NHS costs only) Number of NICE publications Cost of NICE guidance per patient Rheumatoid arthritis 600 million 7 7.50 317,000 Dementia 3.5 billion 3 2.30 665,000
Involving the public People with personal experience of the condition, illness or health problem Relatives and carers Members of organisations representing patient and public interests Advocates and other relevant staff from organisations representing patient and public interests Members of the general public
What do patients and the public provide to NICE? The personal impact of an illness, disease or condition Experiences of care Preferences and values Outcomes people want from treatment and care Impact of treatment or care on outcome, symptoms, physical & social functioning, quality of life Impact on family, friends and employers Ease of use of a treatment or service; side effects The needs of specific groups Challenges to professional or researcher views Areas needing further research
Patient preferences Example - kidney dialysis Committee assumed patients would prefer dialysis at home Some patients told us they disliked home machines as it meant their illness dominated their lives
Patients experience of care Example people who self-harm People in mental distress who self-harm told us that they were not routinely offered anaesthesia or pain relief for sewing up wounds in the hospital emergency department Nothing in the published research to indicate this was an issue NICE made recommendations to address this
NICE quality standards A set of statements that outline what high quality care for a specific disease or condition should look like.
Quality standards - policy background New focus on quality - the birth of NICE quality standards Focus on quality retained - strengthened role for NICE quality standards NICE quality standards - underpin the new commissioning system High Quality Care for All Health & Social Care Act 2012 Developing the NHS Commissioning Board
Quality Standards A comprehensive set of recommenda/ons for a par/cular disease or condi/on Evidence Guidance Quality Standards Sen2nel markers A prioritised set of concise, measureable statements designed to drive quality improvements across a pathway of care
180 healthcare topics
Uptake of recommendations Has NICE guidance had any impact? NICE has an ongoing programme of monitoring data on uptake from external sources Examples of data on uptake for: Workplace and public health Bariatric surgery Antibiotic prophylaxis
Uptake of guidance on antibiotic prophylaxis Advice not to give for routine dental procedures Total number of prescriptions for antibiotic prophylaxis (amoxicillin 3 g or clindamycin 600 mg) dispensed each month by type of prescriber. Thornhill M H et al. BMJ 2011;342:bmj.d2392 2011 by British Medical Journal Publishing Group
and no change in rates of endocarditis Proportion of infective endocarditis cases recorded each month with a code for streptococci or staphylococci as cause. Red lines represent moving average figure for cases every three months Thornhill M H et al. BMJ 2011;342:bmj.d2392 2011 by British Medical Journal Publishing Group
Patients assessed on admission for VTE risk CG92 Published Jan 2010 CG92 1.1.1: Assess all patients on admission to identify those who are at increased risk of VTE. 100% 98,66% Propor2on of pa2entes who had VTE risk assessment commpleted 90% 80% 70% 60% 50% 40% 30% 20% 10% 51,50% 6,90% 51,47% 18,52% 19,61% 16,07% 69,64% 79,20% 79,17% Basey AJ et al. (2012) Bateman AG et al (2012) Child S et al (2014) Thavarajah D, & Wetherill M (2012) 0% 31/10/2009 31/01/2010 25/06/2010 30/04/2011 Date
Key access routes to date
Challenges Future challenges: Integration agenda Evidence base e.g. social care Focus on standards and indicators Multimorbidity Keeping everything up-to-date Reduced funding for healthcare